Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 15/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595435 | 0.84 | CA12 (0.38) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL11076 | 0.72 | — | — | |
| SCHEMBL103232 | 0.72 | ITGB2 (0.50) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL29945033 | 0.72 | ITGB2 (0.50) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL29664379 | 0.72 | — | — | |
| SCHEMBL29568932 | 0.70 | CA12 (0.38) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL218235 | 0.70 | CA12 (0.38) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL3457558 | 0.70 | — | — | |
| SCHEMBL20898034 | 0.69 | CHRNB4 (0.41) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL11121 | 0.69 | ABCG2 (0.50) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352734-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010043714-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-7109213-B2 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2006-09-19 | — | — | US | disclosed |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. | 2006-01-19 | — | — | US | disclosed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | disclosed |
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | NPEPPS, AASDHPPT, DNPEP | LTA4H 1326/4885CA12 4874/4885CA1 4866/4885 |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | LTA4H 2089/4885CA12 4644/4885CA1 4148/4885 |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | AZI2, NPEPPS, AMPD2 | LTA4H 2291/4885CA12 4815/4885CA1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.